London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm off now , as Donaldt posted a few weeks ago , you were warned when he posted 18 months back.
SAX just needs Zenagh back here to bounce off again.
Cashed up into q1 2023.
I sold , I can see reason to buy here any time before next July @ 120p
Heam
Haematokine gets quite a bit of attention , again , with the potential for partnerships whilst still in trial and relatively quick entry into market ( compared to some )
Yet Traumakine gets no mention at all.
Bet cannot get traction , along with Traumakine , but hey , lets just flag up Team again to deflect attention.
And then we'll just grab a few more quid via a placing and dilute the small guys.
And no SSV to be seen.
Quite a detailed analyst report there .
I'm translating chunks , but it seems they have done a lot of research into Bex potential , spinoffs , and future incomes.
Bexmab looks like the front runner to secure some kind of partnership deal - quickest to market and providing a revenue stream .
Traumakine predictions not included here , as the direction is not yet set , so they can't include any forecast for income as it stands , although news is expected in 2022 as to where its going next .
Haematokine gets quite a bit of attention , again , with the potential for partnerships whilst still in trial and relatively quick entry into market ( compared to some )
Faron has announced that it is recruiting staff for its US office in Boston. In addition to clinical research staff, the company has also recruited IR staff. Indeed, the company's management has mentioned an IPO in the US as one possibility for financing the company.
In addition, the company has the possibility of seeking funding from its existing marketplaces on the London AIM and Nasdaq First North. The company said that in summer 2022, it had arranged a directed issue of EUR 5 MEUR, which we understand will cover one third of the EUR 15 MEUR required by the loan agreement. We estimate that Faron will seek to raise the remaining 10 MEUR under the terms of the loan through a share issue between Q3'22-Q1'23. If the offering is completed, we estimate that the offering will be executed at a discount of around 10%. The latest offering was completed at the market price.
A third potential source of funding for the company is global or regional collaboration agreements with large pharmaceutical companies. We believe this would be relevant for Phase II/III trials, where the partner would bear part of the cost of the trial and, once the drug is on the market, would handle its sales, marketing and distribution. Faron's first Phase II/III trial is MATINS, which is investigating the efficacy of BEX as a monotherapy in patients with end-stage cancer. We consider a collaboration agreement on MATINS to be possible.
However, we believe that the more likely subject of a collaboration agreement is the late-stage BEXCOMBO study (BEX combined with PD-1 inhibitor). Similarly, we see strong potential for an agreement in the next phases of BEXMAB (BEX combined with standard therapy) and BEXLUNG (BEX combined with PD-1 inhibitor).
The commercial potential is therefore very high. In terms of commercialisation, we believe Faron will seek to enter into a collaboration agreement with a large pharmaceutical company.
This would provide Faron with resources for drug development, milestone payments, licensing revenues and access to the partner's global sales, marketing and distribution organisation.
Faron's revenue streams are most likely to start accruing from 2026 and peak in the mid-2030s, before bexmarilimab patents expire. The company's current cash position is sufficient to cover expenses until Q1'23 and we expect the company to issue shares in H2'22H1'23.
A successful issuance would also allow us to raise the debt financing tied to the issue. We also expect the company to actively pursue a development and commercialisation agreement with a larger pharmaceutical company in the near future.
Thanks
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, will report unaudited half-year financial results for the six months ended June 30, 2022 on Thursday, August 25, 2022 at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST).
A virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and Toni Hänninen, Chief Financial Officer, at 7:00 am (EDT) / 12:00 pm (BST) / 2:00 pm (EEST) on the day of results.
Webcast registration link: https://faron.videosync.fi/2022-halfyear-results
The half-year report, presentation, and a replay of the webcast will be available on the Company's website at www.faron.com/investors
Sax is there a link to the Q&A I can't see it.
There is an updated report 8.8.2022 on their investors website but its not in English. The usual time scale roadmaps, progress, some strategy talk. looks busy Q3 Q4 2022 though.
https://www.faron.com/investors
There is a Q&A on the 25th , but in the past they seem to just stick mainly to the analysts questions , and brief at that .
I did get one in about Eric last time , and Toni answered , so it's worth trying .
You'd hope they would use this opportunity to spin out some good news , what with the SP being on the floor .
….what comes to bexmab
My guess is that the first results are:
a) not that impressive as thought but still useful, or
b) extremely good and needs careful processing and further plans for consecutive steps not only in blood cancer but also in solid ones.
Would love another Q&A session have a few pointed questions I'd like to ask, anyway hope it's the calm before the SSV